Inhibition of the type I insulin-like growth factor receptor expression and signaling: Novel strategies for antimetastatic therapy

Biochemical Pharmacology

Volumn 60, Issue 8, 2000, Pages 1101-1107

  Brodt, Pnina ^a   Samani, Amir ^a   Navab, Roya ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cancer metastasis; IGF I receptor; Signal transduction

Indexed keywords

ANTIMETASTATIC AGENT; COMPLEMENTARY RNA; EPIDERMAL GROWTH FACTOR; FOCAL ADHESION KINASE; INSULIN; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C RECEPTOR;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; CANCER INVASION; HUMAN; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0034668185     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00422-6     Document Type: Article

References (68)

1. Boring C.C., Squires T.S., Tong T., Montgomery S. Cancer Statistics, 1994. CA Cancer J Clin. 448:1994;7-26.
2. Fidler I.J., Balch C.M. The biology of cancer metastasis and implications for therapy. Curr Probl Surg. 24:1987;129-209.
3. Brodt P, Adhesion receptors and proteolytic mechanisms in cancer invasion and metastasis. In: Cell Adhesion and Invasion in Cancer Metastasis (Ed. Brodt P), pp. 167-242. R.G. Landes and Springer, Heidelberg and Austin TX, 1996.
4. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis An imbalance of positive and negative regulation . Cell. 64:1991;327-336.
5. Pardee A.B. G1 events and regulation of cell proliferation. Science. 246:1989;603-608.
6. Yarden Y., Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 57:1988;443-478.
7. Pawson T. Protein modules and signalling networks. Nature. 373:1995;573-580.
8. Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C., Henzel W., Le Bon T., Kathuria S., Chen E., et al. Insulin-like growth factor I receptor primary structure Comparison with insulin receptor suggests structural determinants that define functional specificity . EMBO J. 5:1986;2503-2512.
9. Massague J., Czech M.P. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem. 257:1982;5038-5045.
10. LeRoith D., Clemmons D., Nissley P., Rechler M.M. Insulin-like growth factors in health and disease. Ann Intern Med. 116:1992;854-862.
11. Sara V.R., Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev. 70:1990;591-614.
12. Clemmons D.R. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 140:1998;19-24.
13. Baserga R., Hongo A., Rubini M., Prisco M., Valentinis B. The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta. 1332:1997;F105-F126.
14. Rubin R., Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest. 73:1995;311-331.
15. Coppola D., Ferber A., Miura M., Sell C., D'Ambrosio C., Rubin R., Baserga R. A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol. 14:1994;4588-4595.
16. DeAngelis T., Ferber A., Baserga R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor. J Cell Physiol. 164:1995;214-221.
17. Harrington E.A., Bennett M.R., Fanidi A., Evan G.I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 13:1994;3286-3295.
18. Rodriguez-Tarduchy G., Collins M.K., Garcia I., Lopez-Rivas A. Insulin-like growth factor-I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol. 149:1992;535-540.
19. Resnicoff M., Abraham D., Yutanawiboonchai W., Rotman H.L., Kajstura J., Rubin R., Zoltick P., Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 55:1995;2463-2469.
20. Butler A.A., Yakar S., Gewolb I.H., Karas M., Okubo Y., LeRoith D. Insulin-like growth factor-I receptor signal transduction At the interface between physiology and cell biology . Comp Biochem Physiol B Biochem Mol Biol. 121:1998;19-26.
21. Petley T., Graff K., Jiang W., Yang H., Florini J. Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res. 31:1999;70-76.
22. White M.F. The insulin signaling system and the IRS proteins. Diabetologia. 2:1997;S2-S17.
23. Craparo A., O'Neill T.J., Gustafson T.A. Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor. J Biol Chem. 270:1995;15639-15643.
24. Giorgetti S., Ballotti R., Kowalski-Chauvel A., Tartare S., Van Obberghen E. The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem. 268:1993;7358-7364.
25. Sugimoto S., Wandless T.J., Shoelson S.E., Neel B.G., Walsh C.T. Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. J Biol Chem. 269:1994;13614-13622.
26. Sun X.J., Crimmins D.L., Myers M.G. Jr, Miralpeix M., White M.F. Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1. Mol Cell Biol. 13:1993;7418-7428.
27. Skolnik E.Y., Batzer A., Li N., Lee C.H., Lowenstein E., Mohammadi M., Margolis B., Schlessinger J. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science. 260:1993;1953-1955.
28. Valentinis B., Romano G., Peruzzi F., Morrione A., Prisco M., Soddu S., Cristofanelli B., Sacchi A., Baserga R. Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J Biol Chem. 274:1999;12423-12430.
29. Gual P., Baron V., Lequoy V., Van Obberghen E. Interaction of Janus kinases JAK-1 and JAK-2 with the insulin receptor and the insulin-like growth factor-1 receptor. Endocrinology. 139:1998;884-893.
30. Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., Wang L.H. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem. 275:2000;15099-15105.
31. Zong C.S., Zeng L., Jiang Y., Sadowski H.B., Wang L.H. STAT3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth. J Biol Chem. 273:1998;28065-28072.
32. Beitner-Johnson D., LeRoith D. Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. J Biol Chem. 270:1995;5187-5190.
33. Koval A.P., Karas M., Zick Y., LeRoith D. Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-I receptor-mediated signal transduction. J Biol Chem. 273:1998;14780-14787.
34. Baron V., Calleja V., Ferrari P., Alengrin F., Van Obberghen E. p125Fak focal adhesion kinase is a substrate for the insulin and insulin-like growth factor-I tyrosine kinase receptors. J Biol Chem. 273:1998;7162-7168.
35. Casamassima A., Rozengurt E. Insulin-like growth factor I stimulates tyrosine phosphorylation of p130 (Cas), focal adhesion kinase, and paxillin. Role of phosphatidylinositol 3′-kinase and formation of a p130 (Cas). Crk complex. J Biol Chem. 273:1998;26149-26156.
36. Prager D., Li H.L., Yamasaki H., Melmed S. Human insulin-like growth factor I receptor internalization. Role of the juxtamembrane domain. J Biol Chem. 269:1994;11934-11937.
37. Dews M., Nishimoto I., Baserga R. IGF-I receptor protection from apoptosis in cells lacking the IRS proteins. Recept Signal Transduct. 7:1997;231-240.
38. Li S., Ferber A., Miura M., Baserga R. Mitogenicity and transforming activity of the insulin-like growth factor-I receptor with mutations in the tyrosine kinase domain. J Biol Chem. 269:1994;32558-32654.
39. Hernandez-Sanchez C., Blakesley V., Kalebic T., Helman L., LeRoith D. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation and tumorigenesis. J Biol Chem. 270:1995;29176-29181.
40. O'Connor R. Survival factors and apoptosis. Adv Biochem Eng Biotechnol. 62:1998;137-166.
41. Miura M., Surmacz E., Burgaud J.L., Baserga R. Different effects on mitogenesis and transformation of a mutation at tyrosine 1251 of the insulin-like growth factor I receptor. J Biol Chem. 270:1995;22639-22644.
42. Blakesley V.A., Koval A.P., Stannard B.S., Scrimgeour A., LeRoith D. Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth. J Biol Chem. 273:1998;18411-18422.
43. Li S., Resnicoff M., Baserga R. Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor. J Biol Chem. 271:1996;12254-12260.
44. Macaulay V.M. Insulin-like growth factors and cancer. Br J Cancer. 65:1992;311-320.
45. Hankinson S.E., Willette W.C., Colditz G.A., Hunter D.J., Michaud D.S., Deroo B., Rosner B., Speizer F.E., Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 351:1998;1373-1375.
46. Mantzoros C.S., Tzonou A., Signorello L.B., Stampfer M., Trichopoulos D., Adami H.O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer. 76:1997;1115-1118.
47. Ma J., Pollak M.N., Giovannucci E., Chan J.M., Tao Y., Hennekens C.H., Stampfer M.J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst. 91:1999;620-625.
48. Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 54:1994;4848-4850.
49. Burfeind P., Chernicky C.L., Rininsland F., Ilan J., Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA. 93:1996;7263-7268.
50. Nakamura K., Hongo A., Kodama J., Miyagi Y., Yoshinouchi M., Kudo T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res. 60:2000;760-765.
51. Pietrzkoski Z., Mulholland G., Gomella L., Jameson B.A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53:1993;1102-1106.
52. Rininsland F., Johnson T.R., Chernicky C.L., Schulze E., Burfeind P., Ilan J. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Proc Natl Acad Sci USA. 94:1997;5854-5859.
53. Baserga R. Controlling IGF-receptor function A possible strategy for tumor therapy . Trends Biotech. 14:1996;150-152.
54. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 253:1999;1-6.
55. Long L., Nip J., Brodt P. Paracrine growth stimulation by hepatocyte-derived insulin-like growth factor-1 A regulatory mechanism for carcinoma cells metastatic to the liver . Cancer Res. 54:1994;3732-3737.
56. Long L., Rubin R., Brodt P. Enhanced invasion and liver colonization by lung carcinoma cells overexpressing the type 1 insulin-like growth factor receptor. Exp Cell Res. 238:1998;116-121.
57. Long L., Rubin R., Baserga R., Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res. 55:1995;1006-1009.
58. r 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res. 58:1998;3243-3247.
59. Burgaud J.L., Resnicoff M., Baserga R. Mutant IGF-I receptors as dominant negatives for growth and transformation. Biochem Biophys Res Commun. 214:1995;475-481.
60. Reiss K., D'Ambrosio C., Tu X., Tu C., Baserga R. Inhibition of tumor growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect. Clin Cancer Res. 4:1998;2647-2655.
61. Jiang Y., Rom W.N., Yie T.A., Chi C.X., Tchou-Wong K.M. Induction of tumor suppression and glandular differentiation of A549 lung carcinoma cells by dominant-negative IGF-1 receptor. Oncogene. 44:1999;6071-6077.
62. Bergeron J.J., Cruz J., Khan M.N., Posner B.I. Uptake of insulin and other ligands into receptor-rich endocytic components of target cells The endosomal apparatus . Annu Rev Physiol. 47:1985;383-403.
63. Chow J.C., Condorelli G., Smith R.J. Insulin-like growth factor-I receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway. J Biol Chem. 273:1998;4672-4680.
64. Zapf A., Hsu D., Olefsky J.M. Comparison of the intracellular itineraries of insulin-like growth factor-I and insulin and their receptors in Rat-1 fibroblasts. Endocrinology. 134:1994;2445-2451.
65. Furlanetto R.W. Receptor-mediated endocytosis and lysosomal processing of insulin-like growth factor I by mitogenically responsive cells. Endocrinology. 122:1988;2044-2053.
66. Authier R., Metioui M., Bell A.W., Mort J.S. Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J Biol Chem. 274:1999;33723-33731.
67. Xing R., Wu F., Mason R.W. Control of breast tumor cell growth using a targeted cysteine protease inhibitor. Cancer Res. 58:1998;904-909.
68. Navab R., DiGulielmo G.M., Bergeron J.J., Brodt P. Cysteine proteinases can regulate the malignant phenotype through their involvement in IGF-1 receptor turnover. Proc Am Assoc Cancer Res. 40:1999;4043.